Thomas Malcolm, Ph.D.
Dr. Thomas Malcolm is a founder of Excision BioTherapeutics and currently serves as CEO and President. Prior to founding Excision, Thomas served as the CEO of Criterion BioScience Research Group, a life sciences consulting group based in New York, NY that specialized in analyzing and advising on biotechnologies. In addition to his current position, Thomas serves as a scientific officer and board member for BioMark Diagnostics Inc., a company developing industry-disruptive metabolomic diagnostics for cancers.
Dr. Malcolm has over 16 years of experience in the field of HIV-1 biochemistry and epigenetics in relation to transcriptional latency gene models associated with the virus. Moreover, he has worked on multiple research projects involving gene regulation and cell signaling biochemistry in relation to many cancers. He has completed cancer research terms at Mount Sinai School of Medicine and Memorial Sloan Kettering Cancer Center in New York, NY. In addition to his experience in the viral and cancer fields, he worked at Siemens Healthcare Diagnostics as a Senior Biochemist directing researchers in the development of small molecule competitive ELISA-based assays to monitor the levels of immunosuppressants used for organ recipient patients.
Dr. Malcolm has published his work on HIV and cancer in multiple high impact and peer-reviewed journals. He is also a co-inventor of numerous technologies in the metabolomic diagnostics and viral-focused arenas. Thomas earned his Ph.D. in Biochemistry and Molecular Biology from the University of British Columbia, Vancouver, Canada.